---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-066593"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:52:06.668889+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# KALA BIO completes enrollment in Phase 2b trial of KPI-012 for PCED; topline data expected Q3 2025

## Summary
- CHASE trial randomized 79 patients across 37 sites in US and Latin America.
- Two doses of KPI-012 (3 U/mL and 1 U/mL) vs vehicle, dosed QID for 56 days.
- Primary endpoint: complete healing of PCED by corneal fluorescein staining photos (masked central reading).
- Company expects to report topline data in Q3 2025; trial may serve as pivotal for BLA submission.
- If positive, CHASE could potentially support BLA to FDA after regulatory discussion.

## SEC filing metadata
- accession: 0001104659-25-066593
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000110465925066593/0001104659-25-066593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000110465925066593/tm2520099d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-066593
- JSON: https://secwatch.observer/filing/0001104659-25-066593.json
- Plain text: https://secwatch.observer/filing/0001104659-25-066593.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.